// App-Quantinova.ai

663 : Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States.

Researchers

Presenter

  • Kimberly Lowe

Principal Investigators

  • Tamer Garawin

  • Michael Anthony Kelsh

  • Gerry C. Bohac

Medical Centers

  • Amgen, Seattle, WA

  • Amgen Inc, Thousand Oaks, CA

  • Center for Observational Research, Amgen, Inc., Thousand Oaks, CA

  • Amgen Inc, Thousand Oaks, CA

Locations

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Solid malignancies

  • Colorectal Cancer

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Bevacizumab

  • panitumumab

  • Erbitux

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved